ALTSTATION.IO

Ventas, Inc. (VTR) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$81.36

Change

+1.91%

Market Cap

$38.22B

Avg Volume

2.9M

Company Overview

Ventas, Inc. (VTR) is a major player in the real estate investment trust (REIT) sector, specifically focusing on healthcare facilities. Headquartered in Chicago, Ventas owns and operates around 1,400 properties across North America and the UK, including over 850 senior housing communities. Their services cater primarily to the aging population, providing environments that support healthy living and healthcare needs.

In terms of competitive positioning, Ventas is a market leader within the REIT healthcare space. Their scale and diverse portfolio—which includes outpatient medical buildings and research centers—provide them with a significant edge. They maintain strong relationships across the healthcare sector but face competition from firms like Welltower and HCP. Market dynamics such as demographic shifts toward an aging population and increased demand for healthcare services play to Ventas’s strengths, although economic factors and regulatory changes pose ongoing threats.

Currently, Ventas is in a phase of strategic growth, leveraging operational insights and a strong financial position to expand its offerings. They’ve recently made moves to optimize their portfolio, focusing on high-demand areas and divesting from underperforming assets. With these shifts, Ventas is poised to capitalize on the longevity economy, positioning itself for continued performance improvement in the coming years.

Key Financials

Market Cap

$38.22B

Revenue

$5.54B

EBITDA

$2.11B

Gross Margin

41.9%

Profit Margin

4.3%

Revenue Growth

21.8%

Total Cash

$188.62M

Total Debt

$12.79B

Free Cash Flow

$1.07B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

153.52

Forward P/E

84.76

Beta

0.77

52-Week High

$81.89

52-Week Low

$58.72

EPS

$0.53

50-Day Avg

$78.16

200-Day Avg

$70.43

Price/Book

3.09

Technical Analysis

Over the 52-week period, Ventas, Inc. (VTR) has displayed a clear uptrend, with a substantial increase of 42.0%, rising from a low around $55 to its current price of $81.36. Key support is seen at the $65 level, which held during several pullbacks, while resistance is notable near $82.55, where the stock has struggled to break through recently. A bullish pattern is forming, characterized by higher lows and higher highs, indicating strong buying pressure. In the last few weeks, the stock has shown positive momentum, breaching the previous resistance level and testing the upper range. The current price at $81.36 is approaching the 52-week high, suggesting strong bullish sentiment and the potential for further upside if it can maintain above the recent highs.

Recent News and Developments

Here’s a summary of the latest news and developments for Ventas, Inc

(VTR) stock over the past week:

1. Ventas Exceeds Q4 2025 Earnings Expectations, Raises Dividend, and Provides Strong 2026 Outlook

Ventas, Inc. reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, significantly surpassing analyst estimates. The company posted earnings per share (EPS) of $0.89 for Q4 2025, beating the anticipated $0.41 by over 117%, and reported revenue of $1.57 billion, exceeding the $1.5 billion consensus. Furthermore, Ventas issued a confident outlook for full-year 2026, projecting normalized FFO per share in the range of $3.78 to $3.88, an 8% increase year-over-year, and approved an 8% dividend increase.

2. Ventas Stock Reaches All-Time High Amidst Positive Performance

Following its robust earnings report and optimistic 2026 guidance, Ventas, Inc. (VTR) stock achieved an all-time high of $81.91 on February 6, 2026. The stock experienced a gain of 3.39% on February 6, 2026, rising from $79.84 to $82.55, marking its fourth consecutive day of gains and an increase of 7.22% over the past two weeks. This upward movement reflects investor confidence in the healthcare REIT’s strong operational performance, particularly within its senior housing portfolio.

Market Sentiment and Analyst Recommendations

Bull Case

Ventas just crushed Q4 earnings with 117% EPS beat and delivered 8% FFO growth guidance for 2026. The company is aggressively deploying capital into senior housing with $800M closed year-to-date and a $2.5B target for 2026, which directly funds that projected high single-digit FFO growth. Management raised the dividend 8% on the back of strong operational performance, signaling confidence in the cash generation machine. The stock is up 42% over 52 weeks with clear technical support at $65 and resistance being broken near $82.55, reflecting real momentum. At a 153 P/E the valuation looks absurd on paper, but that’s because earnings are artificially depressed right now — the normalized FFO guidance of $3.78-$3.88 suggests the company is firing on all cylinders. Healthcare REITs benefit from aging demographics and sticky tenant relationships, and Ventas has nearly 1,400 properties across North America and the UK providing revenue diversification.

Bear Case

That 153 P/E is a screaming red flag even if FFO tells a different story. Ventas carries $12.79B in debt against only $188.62M in cash, giving it a net debt position of $12.6B that limits financial flexibility if interest rates stay elevated or occupancy rates slip. Senior housing is cyclical and sensitive to labor costs and healthcare reimbursement rates — if either deteriorates, cash flows compress fast. The company is chasing growth through $2.5B in acquisitions this year, which means integration risk and the need to deploy capital at acceptable returns in a competitive market. Revenue growth of 21.8% is strong but heavily dependent on those acquisitions closing smoothly; organic growth from existing properties is likely much lower. If the Fed keeps rates higher for longer, cap rates on real estate stay elevated, making new deals less accretive to FFO than management assumes.

What to Watch

Monitor Q1 2026 earnings in May for normalized FFO delivery against the $3.78-$3.88 guidance range and any changes to the $2.5B acquisition target. Track senior housing occupancy rates quarterly — a decline below 85% would signal tenant stress and pressure margins. Watch for debt reduction progress; if net leverage stays above 5x EBITDA, the dividend hike becomes riskier. The stock needs to hold above $82.55 to confirm the breakout; a close below $75 would break the bullish pattern and suggest profit-taking. Keep an eye on interest rate movements and 10-year Treasury yields; a spike above 4.5% would likely cap cap rates and slow acquisition returns. Finally, monitor competitor announcements in senior housing consolidation — if rivals snag better assets or announce better returns on capital, Ventas’ growth thesis weakens.

Analyst Consensus

BUY

Based on 20 analyst opinions

Low Target

$80.00

Mean Target

$86.50

High Target

$94.00

Earnings and Financial Data

Sector

Real Estate

Industry

REIT – Healthcare Facilities

Employees

498

Earnings & Dividends

Next Earnings

Apr 29, 2026

EPS (Trailing)

$0.53

Dividend Yield

240.0%

Payout Ratio

356.6%

Frequently Asked Questions

Is VTR a good stock to buy?

Yes, Ventas, Inc. (VTR) is currently rated as a BUY by analysts, with a price target of $86.50. The stock’s solid position in the healthcare REIT sector and strong market cap of $38.22 billion support this recommendation.

What is VTR’s price target?

The analyst price target for VTR is $86.50. This suggests a potential upside of about 6.5% from the current price of $81.36.

Does VTR pay a dividend?

Yes, Ventas offers a substantial dividend yield of 240.0%. This makes it an attractive option for income-focused investors in the real estate sector.

What is VTR’s current P/E ratio?

VTR has a high P/E ratio of 153.52 and a forward P/E of 84.76. These figures indicate that the stock is considered expensive relative to current earnings but could signal growth expectations.

What’s VTR’s 52-week range?

VTR’s stock price has fluctuated between $58.72 and $81.89 over the past 52 weeks. This range shows it has gained traction recently, reflecting positive momentum in the healthcare REIT market.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.